RESULTS

Base case scenario

Compared to ICS alone, SCIT + ICS administered over three years in a 10-year time horizon would avert a total of 847 exacerbations per 1,000 patients treated. These results along with medication discontinuation would generate 0.37 additional QALYs (3.7 months) and additional $836 costs per patient. These clinical gains are projected to come at a higher total cost resulting from the additional cost of SCIT administration in the first three years of the model (76.7%). Only a small proportion of these costs (5.2%) would be compensated through savings in costs associated to ED visits and hospitalizations. These results yielded an ICER below a WTP threshold of $18,125 USD per additional QALY making the SCIT+ICS cost-effective (Table 2).